Literature DB >> 14646329

Spectrophotometric determination of some drugs for osteoporosis.

Elham Anwer Taha1, Nadia Fayek Youssef.   

Abstract

Three simple, accurate and sensitive spectrophotometric methods are developed for the determination of some new drugs for the treatment of osteoporosis: risedronate sodium (I), alendronate sodium (II) and etidronate disodium (III). The first method is based on the measurement of difference in absorbance (Delta A) of risedronate sodium in 0.01 mol l(-1) hydrochloric and 0.1 mol l(-1) sodium hydroxide at 262 nm. Beer's law is obeyed over a concentration range of 15-150 microg ml(-1) with mean recovery 99.75+/-1.22 and molar absorptivity (epsilon) 1.891 x 10(3). The second method is based on the reaction of the primary amino group of (II) with ninhydrin reagent in methanolic medium in the presence of 0.05 mol l(-1) sodium bicarbonate. The colored product is measured at 568 nm, and the linearity range is found to be 3.75-45 microg ml(-1) with mean recovery 99.77+/-0.73 and epsilon 9.425 x 10(3). The third method is based on oxidation of the three mentioned drugs with ceric (IV) sulphate in 0.5 mol l(-1) sulphuric acid at room temperature and subsequent measurement of the excess unreacted cerium (IV) sulphate at 320 nm. The method obeyed Beer's law over a concentration range of 2-24 microg ml(-1) for the three drugs with mean recovery 99.79+/-1.16, 99.73+/-1.38 and 99.86+/-1.13 and epsilon 14.427 x 10(3), 13.813 x 10(3) and 14.000 x 10(3) for drugs I, II, III respectively. The proposed methods were successfully applied for the determination of the studied drugs in bulk powder and in pharmaceutical formulations. The results were found to agree statistically with those obtained the reported methods. Furthermore, the methods were validated according to USP regulations and also assessed by applying the standard addition technique.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646329     DOI: 10.1248/cpb.51.1444

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  10 in total

1.  High-scale yield of nano hydroxyapatite through combination of mechanical activation and chemical dispersion.

Authors:  Xueling Gao; Chunchu Dai; Weiwei Liu; Yumei Liu; Ru Shen; Xiaotong Zheng; Ke Duan; Jie Weng; Shuxin Qu
Journal:  J Mater Sci Mater Med       Date:  2017-04-21       Impact factor: 3.896

2.  Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Authors:  Rebecca S Hayden; Moritz Vollrath; David L Kaplan
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

3.  Complexation of bisphosphonates with ytterbium(III): application of phosphate and ATP detection assay based on Yb(3+)-pyrocatechol violet.

Authors:  Ernestas Gaidamauskas; Helen Parker; Boris A Kashemirov; Alvin A Holder; Kanokkarn Saejueng; Charles E McKenna; Debbie C Crans
Journal:  J Inorg Biochem       Date:  2009-09-20       Impact factor: 4.155

4.  Application of Certain π-Acceptors for the Spectrophotometric Determination of Alendronate Sodium in Pharmaceutical Bulk and Dosage Forms.

Authors:  Asad Raza; Muhammad Zia-Ul-Haq
Journal:  Int J Anal Chem       Date:  2011-06-28       Impact factor: 1.885

5.  Validated spectrophotometric methods for determination of Alendronate sodium in tablets through nucleophilic aromatic substitution reactions.

Authors:  Mohamed I Walash; Mohamed E-S Metwally; Manal Eid; Rania N El-Shaheny
Journal:  Chem Cent J       Date:  2012-04-02       Impact factor: 4.215

6.  Development and Validation of Spectrofluorimetric Method for Determination of Biotin in Bulk and Pharmaceutical Preparations via its Oxidation with Cerium (IV).

Authors:  M I Walash; M Rizk; Z A Sheribah; M M Salim
Journal:  Int J Biomed Sci       Date:  2010-09

7.  Spectrophotometric Determination of Risedronate in Pharmaceutical Formulations via Complex Formation with Cu (II) Ions: Application to Content Uniformity Testing.

Authors:  M I Walash; M E-S Metwally; M Eid; R N El-Shaheny
Journal:  Int J Biomed Sci       Date:  2008-12

8.  Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions.

Authors:  Claire I A van Houdt; Paulo R Gabbai-Armelin; Paula M Lopez-Perez; Dietmar J O Ulrich; John A Jansen; Ana Claudia M Renno; Jeroen J J P van den Beucken
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

9.  Alendronate Sodium Intercalation in Layered Double Hydroxide/Poly (ε-caprolactone): Application in Osteoporosis Treatment.

Authors:  Faranak Baniahmad; Soroor Yousefi; Mohammad Rabiee; Seyedeh Sara Shafiei; Shahab Faghihi
Journal:  Iran J Biotechnol       Date:  2021-01-01       Impact factor: 1.671

10.  Hantzsch pre-column derivatization for simultaneous determination of alendronate sodium and its pharmacopoeial related impurity: Comparative study with synchronous fluorometry using fluorescamine.

Authors:  Amira F El-Yazbi; Eman I El-Kimary; Rasha M Youssef
Journal:  J Food Drug Anal       Date:  2018-06-18       Impact factor: 6.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.